These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

371 related items for PubMed ID: 16675781

  • 1. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis.
    Burman WJ, Goldberg S, Johnson JL, Muzanye G, Engle M, Mosher AW, Choudhri S, Daley CL, Munsiff SS, Zhao Z, Vernon A, Chaisson RE.
    Am J Respir Crit Care Med; 2006 Aug 01; 174(3):331-8. PubMed ID: 16675781
    [Abstract] [Full Text] [Related]

  • 2. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.
    Dorman SE, Johnson JL, Goldberg S, Muzanye G, Padayatchi N, Bozeman L, Heilig CM, Bernardo J, Choudhri S, Grosset JH, Guy E, Guyadeen P, Leus MC, Maltas G, Menzies D, Nuermberger EL, Villarino M, Vernon A, Chaisson RE, Tuberculosis Trials Consortium.
    Am J Respir Crit Care Med; 2009 Aug 01; 180(3):273-80. PubMed ID: 19406981
    [Abstract] [Full Text] [Related]

  • 3. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial.
    Conde MB, Efron A, Loredo C, De Souza GR, Graça NP, Cezar MC, Ram M, Chaudhary MA, Bishai WR, Kritski AL, Chaisson RE.
    Lancet; 2009 Apr 04; 373(9670):1183-9. PubMed ID: 19345831
    [Abstract] [Full Text] [Related]

  • 4. Sputum culture conversion with moxifloxacin-containing regimens in the treatment of patients with newly diagnosed sputum-positive pulmonary tuberculosis in South India.
    Velayutham BV, Allaudeen IS, Sivaramakrishnan GN, Perumal V, Nair D, Chinnaiyan P, Paramasivam PK, Dhanaraj B, Santhanakrishnan RK, Navaneethapandian GP, Marimuthu MK, Kumar V, Kandasamy C, Dharuman K, Elangovan T, Narasimhan M, Rathinam S, Vadivelu G, Rathinam P, Chockalingam C, Jayabal L, Swaminathan S, Shaheed JM.
    Clin Infect Dis; 2014 Nov 15; 59(10):e142-9. PubMed ID: 25028463
    [Abstract] [Full Text] [Related]

  • 5. Adding moxifloxacin is associated with a shorter time to culture conversion in pulmonary tuberculosis.
    Wang JY, Wang JT, Tsai TH, Hsu CL, Yu CJ, Hsueh PR, Lee LN, Yang PC.
    Int J Tuberc Lung Dis; 2010 Jan 15; 14(1):65-71. PubMed ID: 20003697
    [Abstract] [Full Text] [Related]

  • 6. Moxifloxacin versus ethambutol in initial tuberculosis treatment.
    Sellier P, Delcey V, Raskine L, Sanson-Le-Pors MJ, Bergmann JF.
    Lancet; 2009 Jun 27; 373(9682):2198; author reply 2198-9. PubMed ID: 19560598
    [No Abstract] [Full Text] [Related]

  • 7. Moxifloxacin as an alternative or additive therapy for treatment of pulmonary tuberculosis.
    Fouad M, Gallagher JC.
    Ann Pharmacother; 2011 Nov 27; 45(11):1439-44. PubMed ID: 21990937
    [Abstract] [Full Text] [Related]

  • 8. Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial.
    Cevik M, Thompson LC, Upton C, Rolla VC, Malahleha M, Mmbaga B, Ngubane N, Abu Bakar Z, Rassool M, Variava E, Dawson R, Staples S, Lalloo U, Louw C, Conradie F, Eristavi M, Samoilova A, Skornyakov SN, Ntinginya NE, Haraka F, Praygod G, Mayanja-Kizza H, Caoili J, Balanag V, Dalcolmo MP, McHugh T, Hunt R, Solanki P, Bateson A, Crook AM, Fabiane S, Timm J, Sun E, Spigelman M, Sloan DJ, Gillespie SH, SimpliciTB Consortium.
    Lancet Infect Dis; 2024 Sep 27; 24(9):1003-1014. PubMed ID: 38768617
    [Abstract] [Full Text] [Related]

  • 9. Early bactericidal activity of a moxifloxacin and isoniazid combination in smear-positive pulmonary tuberculosis.
    Gillespie SH, Gosling RD, Uiso L, Sam NE, Kanduma EG, McHugh TD.
    J Antimicrob Chemother; 2005 Dec 27; 56(6):1169-71. PubMed ID: 16223939
    [Abstract] [Full Text] [Related]

  • 10. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
    Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR, Pappas F, Phillips PP, Nunn AJ, REMoxTB Consortium.
    N Engl J Med; 2014 Oct 23; 371(17):1577-87. PubMed ID: 25196020
    [Abstract] [Full Text] [Related]

  • 11. A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.
    Rustomjee R, Lienhardt C, Kanyok T, Davies GR, Levin J, Mthiyane T, Reddy C, Sturm AW, Sirgel FA, Allen J, Coleman DJ, Fourie B, Mitchison DA, Gatifloxacin for TB (OFLOTUB) study team.
    Int J Tuberc Lung Dis; 2008 Feb 23; 12(2):128-38. PubMed ID: 18230244
    [Abstract] [Full Text] [Related]

  • 12. Factors influencing time to smear conversion in patients with smear-positive pulmonary tuberculosis.
    Wang JY, Lee LN, Yu CJ, Chien YJ, Yang PC, Tami Group.
    Respirology; 2009 Sep 23; 14(7):1012-9. PubMed ID: 19659516
    [Abstract] [Full Text] [Related]

  • 13. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
    Dawson R, Diacon AH, Everitt D, van Niekerk C, Donald PR, Burger DA, Schall R, Spigelman M, Conradie A, Eisenach K, Venter A, Ive P, Page-Shipp L, Variava E, Reither K, Ntinginya NE, Pym A, von Groote-Bidlingmaier F, Mendel CM.
    Lancet; 2015 May 02; 385(9979):1738-1747. PubMed ID: 25795076
    [Abstract] [Full Text] [Related]

  • 14. Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients.
    Jawahar MS, Banurekha VV, Paramasivan CN, Rahman F, Ramachandran R, Venkatesan P, Balasubramanian R, Selvakumar N, Ponnuraja C, Iliayas AS, Gangadevi NP, Raman B, Baskaran D, Kumar SR, Kumar MM, Mohan V, Ganapathy S, Kumar V, Shanmugam G, Charles N, Sakthivel MR, Jagannath K, Chandrasekar C, Parthasarathy RT, Narayanan PR.
    PLoS One; 2013 May 02; 8(7):e67030. PubMed ID: 23843980
    [Abstract] [Full Text] [Related]

  • 15. Comparative roles of moxifloxacin and levofloxacin in the treatment of pulmonary multidrug-resistant tuberculosis: a retrospective study.
    Jiang RH, Xu HB, Li L.
    Int J Antimicrob Agents; 2013 Jul 02; 42(1):36-41. PubMed ID: 23582696
    [Abstract] [Full Text] [Related]

  • 16. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis.
    Jindani A, Harrison TS, Nunn AJ, Phillips PP, Churchyard GJ, Charalambous S, Hatherill M, Geldenhuys H, McIlleron HM, Zvada SP, Mungofa S, Shah NA, Zizhou S, Magweta L, Shepherd J, Nyirenda S, van Dijk JH, Clouting HE, Coleman D, Bateson AL, McHugh TD, Butcher PD, Mitchison DA, RIFAQUIN Trial Team.
    N Engl J Med; 2014 Oct 23; 371(17):1599-608. PubMed ID: 25337749
    [Abstract] [Full Text] [Related]

  • 17. A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis.
    Conde MB, Mello FC, Duarte RS, Cavalcante SC, Rolla V, Dalcolmo M, Loredo C, Durovni B, Armstrong DT, Efron A, Barnes GL, Marzinke MA, Savic RM, Dooley KE, Cohn S, Moulton LH, Chaisson RE, Dorman SE.
    PLoS One; 2016 Oct 23; 11(5):e0154778. PubMed ID: 27159505
    [Abstract] [Full Text] [Related]

  • 18. Comparison of levofloxacin versus moxifloxacin for multidrug-resistant tuberculosis.
    Koh WJ, Lee SH, Kang YA, Lee CH, Choi JC, Lee JH, Jang SH, Yoo KH, Jung KH, Kim KU, Choi SB, Ryu YJ, Chan Kim K, Um S, Kwon YS, Kim YH, Choi WI, Jeon K, Hwang YI, Kim SJ, Lee YS, Heo EY, Lee J, Ki YW, Shim TS, Yim JJ.
    Am J Respir Crit Care Med; 2013 Oct 01; 188(7):858-64. PubMed ID: 23927582
    [Abstract] [Full Text] [Related]

  • 19. Split-drug regimens for the treatment of patients with sputum smear-positive pulmonary tuberculosis--a unique approach.
    Santha T, Rehman F, Mitchison DA, Sarma GR, Reetha AM, Prabhaker R, Tuberculosis Research Centre, Indian Council of Medical Research.
    Trop Med Int Health; 2004 May 01; 9(5):551-8. PubMed ID: 15117298
    [Abstract] [Full Text] [Related]

  • 20. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months.
    Nolan CM, Goldberg SV.
    Int J Tuberc Lung Dis; 2002 Nov 01; 6(11):952-8. PubMed ID: 12475140
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.